表紙
市場調查報告書
商品編碼
1024619

全球穿戴式心臟去顫器市場:2021∼2028年

Global Wearable Cardioverter Defibrillators Market - 2021-2028

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

充電外部設備穿戴式心臟去顫器 (WCD) 可以全天佩戴在衣服下,保護用戶免受可能危及生命的心室性快速性心律失常。心血管疾病患病率增加有望推動穿戴式心臟復律除顫器市場 。

本報告提供全球穿戴式心臟去顫器市場相關調查,市場概要,以及各症狀,各嵌入類型,各終端用戶,各地區的趨勢,及加入此市場的主要企業簡介等資訊。

目錄

第1章 穿戴式心臟去顫器市場調查手法和範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 穿戴式心臟去顫器市場-市場定義和概要

第3章 穿戴式心臟去顫器市場-摘要整理

  • 各症狀的市場明細
  • 各嵌入類型的市場明細
  • 各終端用戶的市場明細
  • 各地區的市場明細

第4章 穿戴式心臟去顫器市場動態

  • 影響市場的要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 穿戴式心臟去顫器市場-產業分析

  • 波特的五力分析
  • 流行病學分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 穿戴式心臟去顫器市場-COVID-19分析

  • 市場上的Covid-19分析
    • COVID-19前的市場方案
    • COVID-19目前市場方案
    • COVID-19後或未來方案
  • Covid-19的價格動態
  • 需求與供給的頻譜
  • 大流行時的市場相關的政府舉措
  • 製造商策略性舉措
  • 結論

第7章 穿戴式心臟去顫器市場-各症狀

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%),各症狀
    • 市場魅力指數
  • 周產期心肌病
    • 簡介
    • 市場規模分析,百萬美元,2019∼2028年,及與前一年同期比較成長分析(%),2020∼2028年
  • 先天性心臟病
  • 遺傳性心律不整

第8章 穿戴式心臟去顫器市場-各嵌入類型

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%),各嵌入類型
    • 市場魅力指數
  • 植入式心臟去顫器(ICD)
    • 簡介
    • 市場規模分析,百萬美元,2019∼2028年,及與前一年同期比較成長分析(%),2020∼2028年
  • 體外電擊器

第9章 穿戴式心臟去顫器市場-各終端用戶

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%),各終端用戶
    • 市場魅力指數
  • 居家照護
    • 簡介
    • 市場規模分析,百萬美元,2019∼2028年,及與前一年同期比較成長分析(%),2020∼2028年
  • 診療所
  • 門診中心

第10章 穿戴式心臟去顫器市場-各地區

  • 簡介
    • 市場規模分析,百萬美元,2019∼2028年,及與前一年同期比較成長分析(%),2020∼2028年
    • 市場魅力指數
  • 北美
    • 簡介
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%),各症狀
    • 市場規模分析,及與前一年同期比較成長分析(%),各嵌入類型
    • 市場規模分析,及與前一年同期比較成長分析(%),各終端用戶
    • 市場規模分析,及與前一年同期比較成長分析(%),各國
  • 歐洲
    • 簡介
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%),各症狀
    • 市場規模分析,及與前一年同期比較成長分析(%),各嵌入類型
    • 市場規模分析,及與前一年同期比較成長分析(%),各終端用戶
    • 市場規模分析,及與前一年同期比較成長分析(%),各國
  • 南美
    • 簡介
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%),各症狀
    • 市場規模分析,及與前一年同期比較成長分析(%),各嵌入類型
    • 市場規模分析,及與前一年同期比較成長分析(%),各終端用戶
    • 市場規模分析,及與前一年同期比較成長分析(%),各國
  • 亞太地區
    • 簡介
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%),各症狀
    • 市場規模分析,及與前一年同期比較成長分析(%),各嵌入類型
    • 市場規模分析,及與前一年同期比較成長分析(%),各終端用戶
    • 市場規模分析,及與前一年同期比較成長分析(%),各國
  • 中東和非洲
    • 簡介
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%),各症狀
    • 市場規模分析,及與前一年同期比較成長分析(%),各嵌入類型
    • 市場規模分析,及與前一年同期比較成長分析(%),各終端用戶

第11章 穿戴式心臟去顫器市場-競爭情形

  • 主要的發展與策略
  • 企業佔有率分析
  • 產品的基準
  • 值得注意的主要企業的清單
  • 具顛覆性技術的企業的清單
  • Start-Ups企業的清單

第12章 穿戴式心臟去顫器市場-企業簡介

  • Cardiac Science Corporation
    • 企業概要
    • 產品系列和概要
    • 主要的焦點
    • 財務概要
  • ZOLL Medical Corporation
  • Medtronic
  • St. Jude Medical LLC
  • Boston Scientific Corporation
  • Abbot Medical Optics
  • LivaNova
  • Tianjin JingMing New Tech. Devp. Co., Ltd
  • HANSON MEDITEC CO., LTD
  • Huaian Meide Medical Instrument Co., Ltd

非詳細列表

第13章 穿戴式心臟去顫器市場-DataM

  • 附錄
  • 關於本公司、服務
  • 諮詢方式
目錄
Product Code: DMMD3895

Wearable Cardioverter Defibrillators Market Overview

The wearable cardioverter defibrillators market size was valued at US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

The rechargeable external device wearable cardioverter defibrillator (WCD) can be worn under the clothing all day long and protects the user from potentially life-threatening ventricular tachyarrhythmias.

Wearable Cardioverter Defibrillators Market Dynamics

The increase in the prevalence of cardiovascular disease and increasing technological development is assumed to drive the wearable cardioverter-defibrillators in the forecast period.

The increase in the prevalence of the cardiovascular disease is expected to drive the wearable cardioverter defibrillators market

The estimated study of Global Burden of Disease of age-standardized death rate of cardiovascular disease272 per 100,000 population in India is higher than the global average population. According to the Journal of the American College of Cardiology, the number of people dying from cardiovascular disease is rising steadily, globally including one-third of all deaths in 2019, that reviewed the total magnitude of CVD burden and trends over 30 years around the world. Implantable cardioverter defibrillators (ICDs) efficacy has been demonstrated by multiple clinical trials to prevent sudden cardiac death (SCD) among specific high-risk populations. Because of the increasing use of the wearable cardioverter defibrillators and uncertainty of indications among practicing cardiovascular health professionals, this science advisory was prepared by the American Heart Association.

The wearable cardioverter-defibrillator is an alternative antiarrhythmic device that provides continuous cardiac monitoring and defibrillation capabilities through a non-invasive, electrode-based system. The WCD is highly effective at restoring sinus rhythm in patients with ventricular tachyarrhythmia. Using the WCD one randomized trial in patients with recent myocardial infarction at increased risk for arrhythmic death reported a decrease in mortality overall despite no sudden cardiac death mortality benefit. The current clinical indications for WCD use vary and continue to evolve as experience with this technology increases.

The increasing technological development is assumed to drive the wearable cardioverter defibrillators in the forecast period

The implantable cardioverter defibrillator (ICD) is central in the prevention of sudden cardiac death (SCD). Current guidelines recommend ICD implantation for secondary and primary prevention in patients with an established high risk of SCD. Currently, only one WCD system (LifeVest®, ZOLL, Pittsburgh, PA, USA) is available. The WCD is a system that consists of a harness-style vest that contains non-adhesive dry tantalum oxide capacitive sensing electrodes and self-gelling defibrillator electrodes. This lightweight vest (0.8 kg) is designed to be worn continuously under normal clothing and is available in different sizes. A monitor is worn around the waist (or shoulder harness) and contains sensing circuits, batteries, and capacitors. The device has a system of audible and vibratory alerts to warn a patient of an imminent shock. The patient can abort the shock by pressing buttons on the monitor.

Technological advances are considerable in cardiac pacing and defibrillation, from the latest venous accesses for implantation to recent locations for permanent pacing or non-endovenous ICD. The imagination of researchers and device companies seems to be limitless.

The lack of awareness and use of wearable cardioverter defibrillators is expected to hamper the market

Wearable cardioverter-defibrillators (WCD, LifeVest, ZOLL) can protect from sudden cardiac death, bridging a vulnerable period until a decision on implantable cardioverter-defibrillator (ICD) implantation can be reached. WCD is commonly used for three months or less. It is unknown which patients use WCD longer and which patients are most likely to benefit from it. Hypothesis. Extended use of WCD is reasonable in selected cases based on underlying heart disease and overall patient risk profile. Wearable devices can impact directly clinical decision-making. Some users think that wearable technologies improve the quality of patient care by reducing the cost. The big data generated by wearable devices is both a opportunity and challenge for researchers who can apply more artificial intelligence (AI) techniques to these in the future data. Most technologies are still in their prototype stages. Issues such as security ,user acceptance, big data and ethics concerns in this technology l need to be addressedstil to enhance the functions and usability of these devices for practical use.

A wearable cardioverter defibrillator is an option for temporary therapy that can protect patients vulnerable to cardiac arrhythmias by preventing, aborting sudden cardiac death, and lowering mortality rates. Although there are barriers to overcome, promoting consistent identification and increasing awareness may increase the use of this life-saving therapy of thse at high-risk, decrease the current gap in care, and improve clinical decision-making.

COVID-19 Impact Analysis

The healthcare industry has been affected by COVID-19. To curb its growth, government-imposed lockdown. People are fearful they will experience occupational effects and negative health from the COVID-19 pandemic. This has positively affected the wearable cardioverter defibrillators market as people can stay at home and get treated without visiting the doctor in person.

Wearable Cardioverter Defibrillators Market Segment Analysis

The Peripartum Cardiomyopathy segment is expected to dominate the wearable cardioverter defibrillators market

Peripartum cardiomyopathy is a heart muscle weakness that begins sometime during the final month of pregnancy through about five months after delivery, without any other known cause. It is now considered cardiomyopathy of an unknown cause that occurs in the peripartum period in women without pre-existing heart disease. Peripartum cardiomyopathy is relatively rare but devastating, with reported mortality rates between 18% and 56%.

Patients with peripartum cardiomyopathy (PPCM) have sudden cardiac death rates (SCD) of 7-56%; half of these occur <12 weeks of delivery. Ventricular recovery occurs in 30 -50% of PPCM, often within six months. Implantable cardioverter defibrillator (ICD) therapy is used for persistent ventricular dysfunction. SCD risk before ICD implant is unknown. Risk factors for PPCM include non-Caucasian race, gestational hypertension, twin pregnancy, multiparity, and older age. The WCD is composed of four dry, no adhesive electrodes for monitoring, incorporated into a chest strap assembly three defibrillation electrodes and a defibrillation unit carried on a waist belt. The monitoring electrodes are circumferentially positioned around the chest, held by tension from an elastic belt and provides two surface electrocardiogram (ECG) leads. In a vest assembly the defibrillation electrodes are positioned for apex-posterior defibrillation. Proper fitting is required to achieve adequate skin contact to avoid noise and frequent alarms. PPCM patients with severely reduced LVEF have an elevated risk for ventricular tachyarrhythmias early after diagnosis. Therefore, the use of the WCD should be considered in all women with early-stage PPCM and severely reduced LVEF during the first six months after initiation of heart failure therapy.

Implantable Cardioverter Defibrillator (ICD) dominated the wearable cardioverter defibrillators market

A battery-powered device, implantable cardioverter defibrillator that keeps track of the heart rate is placed under the skin. Thin wires connect the ICD to the heart. The device will deliver an electric shock if an abnormal heart rhythm is detected, to restore a normal heartbeat if heart beats chaotically and too fast. They have been very useful in preventing sudden death in patients with sustained, known ventricular tachycardia or fibrillation. Studies have shown that they may prevent cardiac arrest in high-risk patients who haven't had it but are at life-threatening risk for ventricular arrhythmias. It is implanted under the skin, just under the collarbone. It detects arrhythmias and responds with electrical signals to restore your heart's normal rhythm.

They detect and stop arrhythmias. The device continuously monitors heartbeat and delivers electrical pulses to restore when necessary the heart rhythm to normal. It differs from a pacemaker another implantable device used to help control abnormal heart rhythms.It is placed surgically under skin, usually below the left collarbone. One or more flexible, insulated wires run from the ICD through veins to heart. Because the ICD monitors constantly for abnormal heart rhythms and instantly tries to correct them, it helps when the heart stops beating even when patient is far from the nearest hospital. It has become standard treatment cardiac arrest, and are increasingly being used for high risk of sudden cardiac arrest. Sudden death from cardiac arrest can be lowered by ICD risk than medication alone.

The home care settings are assumed to dominate the market

As people mostly prefer home treatment and are spending much on resources to get better treatment at home. Since COVID-19 has made it difficult for patients to visit hospitals, it is easy for physicians to assist patients virtually due to advancements in technology. ZOLL LifeVest is used to detect a life-threatening rapid heart rhythm and automatically deliver a treatment shock to restore a normal rhythm. From detecting a rapid life-threatening heartbeat to automatically delivering a shock, the entire event takes usually less than a minute.

Wearable cardioverter defibrillators does not require the assistance of an emergency personnel or professional for it to work. It can protects patient even when they are alone. With a WCD, patients can continue to do many of the things like spending time without worrying with friends and family, about the risk of SCD. A patient should only remove their ZOLL LifeVest WCD while taking bath or a short shower. If possible, this should be done only when someone is home with the patient,.

Wearable Cardioverter Defibrillators Market Geographical Analysis

North America region is expected to dominate the wearable cardioverter defibrillators market

Due to the growing incidence of diseases, and healthcare system in this region is assumed to dominate the wearable cardioverter defibrillators market.

In the U.S, every 36 seconds a person dies from cardiovascular disease. About 655,000 Americans die from heart disease each year that's 1 in every four deaths. According to a report, nearly half of all U.S. adults have some type of cardiovascular disease, a percentage that reflects recently updated guidelines for treating high blood pressure. High blood pressure also known as hypertension - can lead to heart attack, heart failure and stroke.

On average than any other nation, the United States spends more on health care services than twice as much per person as the other countries. These expenditures are financed by a mixture of complex individual payments, public payers and private insurance There is no single system of health insurance nationwide. The U.S. healthcare system is characterized as the world's most expensive yet least effective compared with other nations. Major healthcare costs drivers are institutionalized medical practices ,technology-induced costs and consumer behavior reimbursement policies. Hence, the increasing incidence of heart diseases and advanced healthcare structures will increase the demand for wearable cardioverter defibrillators.

Wearable Cardioverter Defibrillators Market Competitive Landscape

Major key players in the wearable cardioverter defibrillators market are ZOLL Medical Corporation, Medtronic, St. Jude Medical LLC, Boston Scientific Corporation, LivaNova, Koninklijke Philips N.V., Cardiac Science, Physio-Control Inc., Nihon Kohden Corporation Defibtech LLC, Tianjin JingMing New Tech. Devp. Co., Ltd, HANSON MEDITEC CO., LTD and Huaian Meide Medical Instrument Co., Ltd

Wearable Cardioverter Defibrillators Market Key Companies to Watch

Cardiac Science Corporation

Overview: Cardiac Science Corporation develops, manufactures, and markets diagnostic and therapeutic cardiology products. The Company offers automated external defibrillators, diagnostic workstations, and systems. Cardiac Science serves patients worldwide.

Product Portfolio: Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AEDs), electrocardiograph devices (ECGs), cardiac stress systems and treadmills, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems.

Key Development: ZOLL® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, confirmed that it has completed the previously announced acquisition of Cardiac Science® Corporation, a leading provider of automated external defibrillators (AEDs), related services, and accessories.

Why Purchase the Report?

  • Visualize the composition of the wearable cardioverter defibrillators market Segmentation By Conditions, By Implant Type and End-user highlighting the key commercial assets and players.
  • Identify commercial opportunities in wearable cardioverter defibrillators market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of wearable cardioverter defibrillators market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The wearable cardioverter defibrillators market report would provide an access to an approx. 60 market data table, 50 figures and 180 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Wearable Cardioverter Defibrillators Market - By Conditions

  • Peripartum Cardiomyopathy
  • Congenital Heart Disease
  • Inherited Arrhythmias

Wearable Cardioverter Defibrillators Market - By Implant Type

  • Implantable Cardioverter Defibrillator (ICD)
  • External Cardioverter Defibrillator

Wearable Cardioverter Defibrillators Market - By End-user

  • Home Care settings
  • Clinic
  • Outpatient Centres

Wearable Cardioverter Defibrillators Market - By Region

  • North America
  • Europe
  • South America
  • Asia Pacific
  • Middle East and Africa

Table of Contents

1. Wearable Cardioverter Defibrillators Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Wearable Cardioverter Defibrillators Market - Market Definition and Overview

3. Wearable Cardioverter Defibrillators Market - Executive Summary

  • 3.1. Market Snippet By Conditions
  • 3.2. Market Snippet By Implant Type
  • 3.3. Market Snippet By End-user
  • 3.4. Market Snippet By Region

4. Wearable Cardioverter Defibrillators Market-Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increase in the prevalence of the cardiovascular disease is expected to drive the wearable cardioverter defibrillators market
      • 4.1.1.2. The increasing technological development is assumed to drive the wearable cardioverter defibrillators in the forecast period
    • 4.1.2. Restraints:
      • 4.1.2.1. The lack of awareness and use of wearable cardioverter defibrillators is expected to hamper the market
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Wearable Cardioverter Defibrillators Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. Wearable Cardioverter Defibrillators Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Wearable Cardioverter Defibrillators Market - By Conditions

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Conditions Segment
    • 7.1.2. Market Attractiveness Index, By Conditions Segment
  • 7.2. Peripartum Cardiomyopathy *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Congenital Heart Disease
  • 7.4. Inherited Arrhythmias

8. Wearable Cardioverter Defibrillators Market - By Implant Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Implant Type
    • 8.1.2. Market Attractiveness Index, By Implant Type
  • 8.2. Implantable Cardioverter Defibrillator (ICD)*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. External Cardioverter Defibrillator

9. Wearable Cardioverter Defibrillators Market - By End-user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user Segment
    • 9.1.2. Market Attractiveness Index, By End-user Segment
  • 9.2. Home Care settings *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Clinic
  • 9.4. Outpatient Centres

10. Wearable Cardioverter Defibrillators Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Conditions
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Implant Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Conditions
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Implant Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Conditions
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Implant Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Conditions
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Implant Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Conditions
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Implant Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user

11. Wearable Cardioverter Defibrillators Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch
  • 11.5. List of Company with disruptive technology
  • 11.6. List of Start Up Companies

12. Wearable Cardioverter Defibrillators Market - Company Profiles

  • 12.1. Cardiac Science Corporation*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. ZOLL Medical Corporation
  • 12.3. Medtronic
  • 12.4. St. Jude Medical LLC
  • 12.5. Boston Scientific Corporation
  • 12.6. Abbot Medical Optics
  • 12.7. LivaNova
  • 12.8. Tianjin JingMing New Tech. Devp. Co., Ltd
  • 12.9. HANSON MEDITEC CO., LTD
  • 12.10. Huaian Meide Medical Instrument Co., Ltd

LIST NOT EXHAUSTIVE

13. Wearable Cardioverter Defibrillators Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us